Transcept Pharmaceuticals Overview
- Year Founded
-
2001
- Status
-
Acquired/Merged
- Employees
-
33
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$27.2M
Transcept Pharmaceuticals General Information
Description
Developer of pharmaceuticals designed to address therapeutic needs in the field of neuroscience. The company develops a novel, rapidly absorbed treatment for acute migraine incorporating dihydroergotamine (DHE) as the active drug, thereby enabling patients with migraine to get treated effectively.
Contact Information
Corporate Office
- 1003 West Cutting Boulevard
- Suite 110
- Richmond, CA 94804
- United States
Corporate Office
- 1003 West Cutting Boulevard
- Suite 110
- Richmond, CA 94804
- United States
Transcept Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 12. Merger/Acquisition | 30-Oct-2014 | $27.2M | Completed | Generating Revenue | ||
| 11. Merger/Acquisition | 18-Sep-2013 | Cancelled | Generating Revenue | |||
| 10. 2PO | 25-Apr-2012 | Completed | Generating Revenue | |||
| 9. Reverse Merger | 30-Jan-2009 | Completed | Generating Revenue | |||
| 8. Later Stage VC (Series D) | 08-Mar-2007 | Completed | Generating Revenue | |||
| 7. Debt - General | 05-Jun-2006 | Completed | Generating Revenue | |||
| 6. Later Stage VC (Series C) | 17-Jan-2006 | Completed | Generating Revenue | |||
| 5. Early Stage VC | 02-Jan-2004 | Completed | Generating Revenue | |||
| 4. Early Stage VC (Series B) | 04-Nov-2002 | $36M | $36M | Completed | Generating Revenue | |
| 3. Early Stage VC (Series A) | $9K | Completed | Product Development |
Transcept Pharmaceuticals Patents
Transcept Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20120302616-A1 | Method of treatment of obsessive compulsive disorder with ondansetron | Inactive | 03-Dec-2010 | ||
| WO-2012075288-A1 | Method of treatment of obsessive compulsive disorder with ondansetron | Inactive | 03-Dec-2010 | ||
| US-20120128778-A1 | Compositions and methods for once-daily administration of a trilayer osmotic tablet | Inactive | 23-Nov-2010 | ||
| WO-2012071220-A1 | Compositions and methods for once-daily administration of a trilayer osmotic tablet | Inactive | 23-Nov-2010 | ||
| US-20120128730-A1 | Compositions and methods for once-daily treatment of obsessive compulsive disorder with ondansetron | Inactive | 23-Nov-2010 | A61K9/0004 |
Transcept Pharmaceuticals Signals
Transcept Pharmaceuticals Former Investors (15)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Hamilton BioVentures | Venture Capital | Minority | ||
| InterWest Partners | Venture Capital | Minority | ||
| Montreux Equity Partners | Growth/Expansion | Minority | ||
| New Enterprise Associates | Venture Capital | Minority | ||
| New Leaf Venture | Venture Capital | Minority |
Transcept Pharmaceuticals Acquisitions (2)
Transcept Pharmaceuticals’s most recent deal was a Reverse Merger with Paratek Pharmaceuticals for . The deal was made on 30-Oct-2014.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Paratek Pharmaceuticals | 30-Oct-2014 | Reverse Merger | Pharmaceuticals | ||
| Novacea | 02-Feb-2009 | Merger/Acquisition | Drug Discovery |
Transcept Pharmaceuticals FAQs
-
When was Transcept Pharmaceuticals founded?
Transcept Pharmaceuticals was founded in 2001.
-
Where is Transcept Pharmaceuticals headquartered?
Transcept Pharmaceuticals is headquartered in Richmond, CA.
-
What is the size of Transcept Pharmaceuticals?
Transcept Pharmaceuticals has 33 total employees.
-
What industry is Transcept Pharmaceuticals in?
Transcept Pharmaceuticals’s primary industry is Drug Delivery.
-
Is Transcept Pharmaceuticals a private or public company?
Transcept Pharmaceuticals is a Private company.
-
What is the current valuation of Transcept Pharmaceuticals?
The current valuation of Transcept Pharmaceuticals is .
-
What is Transcept Pharmaceuticals’s current revenue?
The current revenue for Transcept Pharmaceuticals is .
-
How much funding has Transcept Pharmaceuticals raised over time?
Transcept Pharmaceuticals has raised $187M.
-
Who are Transcept Pharmaceuticals’s investors?
Hamilton BioVentures, InterWest Partners, Montreux Equity Partners, New Enterprise Associates, and New Leaf Venture are 5 of 15 investors who have invested in Transcept Pharmaceuticals.
-
When was Transcept Pharmaceuticals acquired?
Transcept Pharmaceuticals was acquired on 30-Oct-2014.
-
Who acquired Transcept Pharmaceuticals?
Transcept Pharmaceuticals was acquired by Paratek Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process